{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:32:50Z","timestamp":1788186770189,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>For patients with atrial fibrillation (AF) and preserved renal function, direct oral anticoagulants (DOACs) are superior to vitamin K antagonists (VKAs) for stroke prevention. However, the evidence in patients with end-stage kidney disease (ESKD) on dialysis remains inconclusive. In this systematic review and meta-analysis, we aim to compare the efficacy and safety of DOACs and VKAs in dialysis patients with nonvalvular AF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      We conducted a systematic literature review of publications comparing DOACs and VKAs in dialysis patients with nonvalvular AF. Data of RCTs and cohort studies were synthesized separately. Outcomes were reported as risk ratios with 95% confidence intervals. Heterogeneity was assessed using\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      statistics.\n                    <\/jats:p>\n                    <jats:p>\n                      Ten studies were included in this meta-analysis: 4 RCTs (DOACs, 269 patients; VKAs, 217) and 6 cohort studies (DOACs, 7039 patients; VKAs, 22,983). In RCTs, the risk for major bleeding was significantly lower with DOACs compared with VKAs (RR 0.64, 95% CI 0.42\u20130.99,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%). In cohort studies, DOAC was associated with a lower risk for all-cause death compared with VKAs; however, with high heterogeneity (RR 0.78, 95% CI 0.62\u20130.98,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200980%). No significant differences were found regarding ischemic stroke or systemic embolism and gastrointestinal bleeding.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In dialysis patients with nonvalvular AF, DOACs were associated with significantly reduced risk for major bleeding in RCTs and significantly reduced risk for all-cause death in cohort studies. These findings suggest that DOACs may provide a higher net clinical benefit compared with VKAs in dialysis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-025-02711-7","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T10:23:21Z","timestamp":1753698201000},"page":"965-979","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonists in dialysis patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-7578","authenticated-orcid":false,"given":"Tian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diona","family":"Gjermeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph B.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"12","key":"2711_CR1","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/ki.2009.477","volume":"77","author":"V Wizemann","year":"2010","unstructured":"Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM (2010) Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77(12):1098\u20131106. https:\/\/doi.org\/10.1038\/ki.2009.477","journal-title":"Kidney Int"},{"issue":"18","key":"2711_CR2","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285(18):2370\u20132375. https:\/\/doi.org\/10.1001\/jama.285.18.2370","journal-title":"JAMA"},{"issue":"4","key":"2711_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jaad.2006.08.065","volume":"56","author":"RH Weenig","year":"2007","unstructured":"Weenig RH, Sewell LD, Davis MDP, McCarthy JT, Pittelkow MR (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56(4):569\u2013579. https:\/\/doi.org\/10.1016\/j.jaad.2006.08.065","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"2711_CR4","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/STROKEAHA.120.028825","volume":"51","author":"E Van Ganse","year":"2020","unstructured":"Van Ganse E, Danchin N, Mah\u00e9 I, Hanon O, Jacoud F, Nolin M, Dalon F, Lefevre C, Cott\u00e9 FE et al (2020) Comparative safety and effectiveness of oral anticoagulants in nonvalvular atrial fibrillation: the NAXOS study. Stroke 51(7):2066\u20132075. https:\/\/doi.org\/10.1161\/STROKEAHA.120.028825","journal-title":"Stroke"},{"issue":"1","key":"2711_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/asheducation-2016.1.188","volume":"2016","author":"C Ribic","year":"2016","unstructured":"Ribic C, Crowther M (2016) Thrombosis and anticoagulation in the setting of renal or liver disease. Hematology 2016(1):188\u2013195. https:\/\/doi.org\/10.1182\/asheducation-2016.1.188","journal-title":"Hematology"},{"issue":"12","key":"2711_CR6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139\u20131151. https:\/\/doi.org\/10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"issue":"10","key":"2711_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883\u2013891. https:\/\/doi.org\/10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"issue":"22","key":"2711_CR8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"issue":"11","key":"2711_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981\u2013992. https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"issue":"12","key":"2711_CR10","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00467-013-2746-7","volume":"29","author":"VM Brandenburg","year":"2014","unstructured":"Brandenburg VM, Sinha S, Specht P, Ketteler M (2014) Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease\u2013mineral and bone disorder. Pediatr Nephrol 29(12):2289\u20132298. https:\/\/doi.org\/10.1007\/s00467-013-2746-7","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"2711_CR11","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/heartjnl-2016-309266","volume":"103","author":"F Yang","year":"2017","unstructured":"Yang F, Hellyer JA, Than C, Ullal AJ, Kaiser DW, Heidenreich PA, Hoang DD, Winkelmayer WC, Schmitt S et al (2017) Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart 103(11):818\u2013826. https:\/\/doi.org\/10.1136\/heartjnl-2016-309266","journal-title":"Heart"},{"issue":"11","key":"2711_CR12","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","volume":"131","author":"KE Chan","year":"2015","unstructured":"Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW (2015) Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131(11):972\u2013979. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.014113","journal-title":"Circulation"},{"issue":"5","key":"2711_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1053\/j.ajkd.2022.03.007","volume":"80","author":"JB Wetmore","year":"2022","unstructured":"Wetmore JB, Weinhandl ED, Yan H, Reyes JL, Herzog CA, Roetker NS (2022) Apixaban dosing patterns versus warfarin in patients with nonvalvular atrial fibrillation receiving dialysis: a retrospective cohort study. Am J Kidney Dis Off J Natl Kidney Found 80(5):569-579.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2022.03.007","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"4","key":"2711_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","volume":"147","author":"H Reinecke","year":"2023","unstructured":"Reinecke H, Engelbertz C, Bauersachs R, Breithardt G, Echterhoff HH, Ger\u00df J, Haeusler KG, Hewing B, Hoyer J et al (2023) A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation 147(4):296\u2013309. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062779","journal-title":"Circulation"},{"issue":"23","key":"2711_CR15","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","volume":"146","author":"SD Pokorney","year":"2022","unstructured":"Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, Bansal N, Gadegbeku CA, Garcia DA et al (2022) Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation 146(23):1735\u20131745. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054990","journal-title":"Circulation"},{"key":"2711_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"2711_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 28:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"2711_CR18","unstructured":"Cochrane Bias Methods Group, Cochrane Non-Randomised Studies Methods Group. ROBINS-I V2 tool. Cochrane Methods Bias [Internet]. 2025 Mar 3; Available from: https:\/\/www.riskofbias.info\/welcome\/robins-i-v2"},{"issue":"6","key":"2711_CR19","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1681\/ASN.2020111566","volume":"32","author":"AS De Vriese","year":"2021","unstructured":"De Vriese AS, Caluw\u00e9 R, Van Der Meersch H, De Boeck K, De Bacquer D (2021) Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol JASN 32(6):1474\u20131483. https:\/\/doi.org\/10.1681\/ASN.2020111566","journal-title":"J Am Soc Nephrol JASN"},{"key":"2711_CR20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000495","author":"Z Harel","year":"2024","unstructured":"Harel Z, Smyth B, Badve SV, Blum D, Beaubien-Souligny W, Silver SA, Clark E, Suri R, Mavrakanas TA et al (2024) Anticoagulation for patients with atrial fibrillation receiving dialysis: a pilot randomized controlled trial. J Am Soc Nephrol JASN. https:\/\/doi.org\/10.1681\/ASN.0000000000000495","journal-title":"J Am Soc Nephrol JASN"},{"issue":"15","key":"2711_CR21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","volume":"138","author":"KC Siontis","year":"2018","unstructured":"Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R et al (2018) Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 138(15):1519\u20131529. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035418","journal-title":"Circulation"},{"issue":"1","key":"2711_CR22","doi-asserted-by":"publisher","first-page":"14679","DOI":"10.1038\/s41598-024-65541-z","volume":"14","author":"JH Roh","year":"2024","unstructured":"Roh JH, Kim YG, Kim D, Park S, Park KS, Kim M, Hwang KW, Hwang W, Park GM et al (2024) Direct oral anticoagulants for oral anticoagulants-na\u00efve Asian patients with atrial fibrillation and end-stage renal disease undergoing dialysis. Sci Rep 14(1):14679. https:\/\/doi.org\/10.1038\/s41598-024-65541-z","journal-title":"Sci Rep"},{"issue":"5","key":"2711_CR23","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s10557-020-07108-4","volume":"35","author":"LC See","year":"2021","unstructured":"See LC, Lee HF, Chao TF, Li PR, Liu JR, Wu LS, Chang SH, Yeh YH, Kuo CT et al (2021) Effectiveness and safety of direct oral anticoagulants in an Asian population with atrial fibrillation undergoing dialysis: a population-based cohort study and meta-analysis. Cardiovasc Drugs Ther 35(5):975\u2013986. https:\/\/doi.org\/10.1007\/s10557-020-07108-4","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"2711_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.japh.2023.12.020","volume":"64","author":"M Moore","year":"2024","unstructured":"Moore M, Vizcaino K, Ewing JA, St VM (2024) Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis. J Am Pharm Assoc JAPhA 64(2):457\u2013462. https:\/\/doi.org\/10.1016\/j.japh.2023.12.020","journal-title":"J Am Pharm Assoc JAPhA"},{"key":"2711_CR25","doi-asserted-by":"publisher","unstructured":"Laville SM, Couchoud C, Bauwens M, Vacher-Coponat H, Choukroun G, Liabeuf S, REIN Collaborators. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2024;39(10):1662\u201371. https:\/\/doi.org\/10.1093\/ndt\/gfae042","DOI":"10.1093\/ndt\/gfae042"},{"issue":"13","key":"2711_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJM196903272801301","volume":"280","author":"G Eknoyan","year":"1969","unstructured":"Eknoyan G, Wacksman SJ, Glueck HI, Will JJ (1969) Platelet function in renal failure. N Engl J Med 280(13):677\u2013681. https:\/\/doi.org\/10.1056\/NEJM196903272801301","journal-title":"N Engl J Med"},{"issue":"3","key":"2711_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.thromres.2005.03.031","volume":"118","author":"DS Lo","year":"2006","unstructured":"Lo DS, Rabbat CG, Clase CM (2006) Thromboembolism and anticoagulant management in hemodialysis patients: a practical guide to clinical management. Thromb Res 118(3):385\u2013395. https:\/\/doi.org\/10.1016\/j.thromres.2005.03.031","journal-title":"Thromb Res"},{"issue":"4","key":"2711_CR28","doi-asserted-by":"publisher","first-page":"e248818","DOI":"10.1001\/jamanetworkopen.2024.8818","volume":"7","author":"CB Olivier","year":"2024","unstructured":"Olivier CB, Stru\u00df L, S\u00fcnnen N, Kaier K, Heger LA, Westermann D, Meerpohl JJ, Mahaffey KW (2024) Accuracy of event rate and effect size estimation in major cardiovascular trials: a systematic review. JAMA Netw Open 7(4):e248818. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.8818","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2711_CR29","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V et al (2021) 2021 European Heart Rhythm Association Practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Eur 23(10):1612\u20131676. https:\/\/doi.org\/10.1093\/europace\/euab065","journal-title":"EP Eur"},{"key":"2711_CR30","doi-asserted-by":"publisher","unstructured":"Chen A, Stecker E, A. Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13):e017559. https:\/\/doi.org\/10.1161\/JAHA.120.017559","DOI":"10.1161\/JAHA.120.017559"},{"key":"2711_CR31","unstructured":"BristolMyers Squibb Company. Prescribing information. Eliquis (apixaban). [Internet]. 2025. Available from: https:\/\/packageinserts.bms.com \u203a pi_eliquis"},{"issue":"1","key":"2711_CR32","doi-asserted-by":"publisher","first-page":"2349114","DOI":"10.1080\/0886022X.2024.2349114","volume":"46","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang J, Shen N, Jiang J, Xie Y (2024) Safety and efficacy of apixaban versus vitamin K antagonists in patients undergoing dialysis: a systematic review and meta-analysis. Ren Fail 46(1):2349114. https:\/\/doi.org\/10.1080\/0886022X.2024.2349114","journal-title":"Ren Fail"},{"issue":"8","key":"2711_CR33","doi-asserted-by":"publisher","first-page":"e034176","DOI":"10.1161\/JAHA.123.034176","volume":"13","author":"T Kao","year":"2024","unstructured":"Kao T, Chen Z, Lin Y (2024) Anticoagulation for patients with concomitant atrial fibrillation and end-stage renal disease: a systematic review and network meta-analysis. J Am Heart Assoc 13(8):e034176. https:\/\/doi.org\/10.1161\/JAHA.123.034176","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"2711_CR34","doi-asserted-by":"publisher","first-page":"e49827","DOI":"10.7759\/cureus.49827","volume":"15","author":"CR Wei","year":"2023","unstructured":"Wei CR, Lim R, Khan S, Ahsan SA, Al Omari M, Sherpa ND, Rashid Z, Khan A (2023) Comparison of the efficacy and safety of left atrial appendage closure and direct oral anticoagulants for atrial fibrillation: a meta-analysis of randomized control trials and observational studies. Cureus 15(12):e49827. https:\/\/doi.org\/10.7759\/cureus.49827","journal-title":"Cureus"},{"issue":"12","key":"2711_CR35","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1093\/ckj\/sfad221","volume":"16","author":"S Genovesi","year":"2023","unstructured":"Genovesi S, Porcu L, Rebora P, Slaviero G, Casu G, Bertoli S, Airoldi F, Buskermolen M, Gallieni M et al (2023) Long-term safety and efficacy of left atrial appendage occlusion in dialysis patients with atrial fibrillation: a multi-center, prospective, open label, observational study. Clin Kidney J 16(12):2683\u20132692. https:\/\/doi.org\/10.1093\/ckj\/sfad221","journal-title":"Clin Kidney J"},{"key":"2711_CR36","unstructured":"Eitel et al. Left atrial appendage closure in patients with non-valvular atrial fibrillation and end-stage chronic kidney disease (LAA-KIDNEY) [Internet]. ClinicalTrials.gov; cited 2025 May 17. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05204212?cond=NCT05204212"},{"issue":"2","key":"2711_CR37","doi-asserted-by":"publisher","first-page":"018","DOI":"10.5837\/bjc.2024.018","volume":"31","author":"MA Sammut","year":"2024","unstructured":"Sammut MA, Elamin N, Storey RF (2024) Factor XI and XIa inhibition: a new approach to anticoagulant therapy. Br J Cardiol 31(2):018. https:\/\/doi.org\/10.5837\/bjc.2024.018","journal-title":"Br J Cardiol"},{"issue":"10333","key":"2711_CR38","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T et al (2022) Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet Lond Engl 399(10333):1383\u20131390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00456-1","journal-title":"Lancet Lond Engl"},{"key":"2711_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejim.2023.08.020","volume":"119","author":"I Kyriakoulis","year":"2024","unstructured":"Kyriakoulis I, Adamou A, Stamatiou I, Chlorogiannis DD, Kardoutsos I, Koukousaki D, Ntaios G (2024) Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: a systematic review and meta-analysis. Eur J Intern Med 119:45\u201352. https:\/\/doi.org\/10.1016\/j.ejim.2023.08.020","journal-title":"Eur J Intern Med"},{"key":"2711_CR40","doi-asserted-by":"publisher","unstructured":"Lin YC, Chen BL, Shih CM, Lin FY, Chen CW, Hsu CY, Kao YT, Bi WF, Chen LY, et al. Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: a real-world nationwide cohort study. Fukumoto Y, editor. PLOS ONE. 2021 Apr 8;16(4):e0249940. https:\/\/doi.org\/10.1371\/journal.pone.0249940","DOI":"10.1371\/journal.pone.0249940"},{"issue":"10","key":"2711_CR41","doi-asserted-by":"publisher","first-page":"1261183","DOI":"10.3389\/fcvm.2023.1261183","volume":"18","author":"JAL Mapili","year":"2023","unstructured":"Mapili JAL, Lim LCS, Velando BM, Aherrera JAM (2023) The safety and efficacy of direct oral anticoagulants among chronic kidney disease patients on dialysis with non-valvular atrial fibrillation: a meta-analysis. Front Cardiovasc Med 18(10):1261183. https:\/\/doi.org\/10.3389\/fcvm.2023.1261183","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"2711_CR42","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2711_CR43","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/pds.4783","volume":"28","author":"N Shehab","year":"2019","unstructured":"Shehab N, Ziemba R, Campbell KN, Geller AI, Moro RN, Gage BF, Budnitz DS, Yang T (2019) Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries. Pharmacoepidemiol Drug Saf 28(7):951\u2013964. https:\/\/doi.org\/10.1002\/pds.4783","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"2711_CR44","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jacc.2017.12.048","volume":"71","author":"KA Hicks","year":"2018","unstructured":"Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR et al (2018) 2017 Cardiovascular and stroke endpoint definitions for clinical trials. J Am Coll Cardiol 71(9):1021\u20131034. https:\/\/doi.org\/10.1016\/j.jacc.2017.12.048","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2711_CR45","doi-asserted-by":"publisher","first-page":"e089353","DOI":"10.1136\/bmjopen-2024-089353","volume":"14","author":"M Ficheux","year":"2024","unstructured":"Ficheux M, Peyro-Saint-Paul L, Balayn D, Lecrux B, Brossier M, Morin A, Lanot A, Peron C, Boulanger M et al (2024) Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non-valvular atrial fibrillation: protocol for a prospective, randomised, open-label, blinded endpoint trial (APIDP2). BMJ Open 14(9):e089353. https:\/\/doi.org\/10.1136\/bmjopen-2024-089353","journal-title":"BMJ Open"},{"key":"2711_CR46","unstructured":"Evans et al. Stroke prophylaxis with apixaban in chronic kidney disease stage 5 patients with atrial fibrillation (SACK) [Internet]. ClinicalTrials.gov; cited 2025 Mar 2. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05679024"},{"key":"2711_CR47","unstructured":"Daiichi Sankyo et al. Vitamin K AntagonISt, Factor Xa inhibitor or nothing in atrial fibrillation and dialytic end-stage renal disease (VISIONAIRE) [Internet]. ClinicalTrials.gov; cited 2025 Mar 2. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06402851"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02711-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:40:09Z","timestamp":1778488809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02711-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2711"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02711-7","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since this work is a systematic review of published literature and uses published data, no additional ethics approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Financial interests: Christoph B. Olivier reports research support from Deutsche Forschungsgemeinschaft, Deutsche Herzstiftung, University of Freiburg, Else Kr\u00f6ner-Fresenius Stiftung, and Haemonetics and received honoraria from Bayer Vital GmbH, BMS, B\u00f6hringer Ingelheim, Daiichi Sankyo, Ferrer, Janssen, and Viatris. Dirk Westermann received honoraria from Abiomed, AstraZeneca, Meril, and Medtronic. All other authors report no disclosures.Non-financial interests: Dirk Westermann is an Editorial Board Member of Clinical Research in Cardiology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}